This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Martin Preyer, Ph.D.
Executive Director, Biotherapeutics at Evolveimmune Therapeutics
Speaker

Profile

Martin Preyer is currently the Executive Director, Biotherapeutics at Evolveimmune Therapeutics, where he is leading the biologics drug discovery and protein engineering team. Before joining Evolveimmune, Martin has led various aspects of biologics drug discovery including the development of ADCs and the engineering of novel bispecific antibody technologies. Among others, he was the head of protein sciences at Revitope Oncology, where he developed a novel platform of protease-activatable T cell engagers for cancer immunotherapy. Martin received his PhD from the University of Natural Resources and Life Sciences in Vienna, Austria, and completed his postdoctoral training in the Laboratory of Genetics at the Salk Institute in La Jolla, CA.

Agenda Sessions

  • EVOLVE: Advanced T Cell Engagers with Integrated CD2 Costimulation

    3:30pm